Peptide of the Week: KPV - 10% Off This Week
Peptide of the Week: KPV - 10% Off This Week
ARA-290, also known as cibinetide, is an 11-amino-acid peptide engineered from the helix B surface region of erythropoietin. In published literature, it is primarily studied for innate repair receptor signaling, inflammatory modulation, small fiber neuropathy research, tissue protection, and repair-related biology. This 2026 research guide covers the molecular profile, proposed mechanisms, experimental findings, and evidence limitations of ARA-290 based strictly on peer-reviewed sources.
ARA-290 (cibinetide) is an 11-amino-acid synthetic peptide derived from the tissue-protective helix B surface region of erythropoietin. It is engineered to activate innate repair receptor signaling without stimulating classical erythropoiesis. Published research has focused primarily on small fiber neuropathy, corneal nerve fiber density, inflammatory modulation, and tissue-protective biology. CAS number: 1208243-50-8. PubChem CID: 91810664.
ARA-290 was designed to isolate the tissue-protective signaling domain of erythropoietin from its hematopoietic activity. Erythropoietin has long been known to stimulate red blood cell production, but research has also revealed a separate tissue-protective biological profile linked to a distinct receptor complex. ARA-290 was engineered to engage that repair-oriented pathway selectively.
ARA-290 is a repair-signaling peptide modeled from erythropoietin but stripped down so researchers can study tissue protection and inflammatory control without the red-blood-cell-stimulating effects EPO is known for. The main scientific question is whether that selective signaling can support better outcomes in nerve, retinal, kidney, and other tissue-stress research models.
ARA-290 sits in a distinctive category among research peptides. Its literature is centered on innate repair biology, making it more accurately understood as a tissue-protective signaling peptide derived from erythropoietin biology than as a general performance or metabolic compound.
ARA-290 has a defined chemical identity confirmed across its published research literature and public chemistry databases.
The proposed mechanisms of ARA-290 center on its selective interaction with a receptor complex distinct from the classical erythropoietic pathway.
| Mechanism | Research Context | Key Observations |
|---|---|---|
| Innate Repair Receptor (IRR) Signaling | Cytoprotection and tissue-repair pathways | ARA-290 is proposed to selectively bind a heteromeric receptor complex involving EPOR and CD131, associated with tissue repair and inflammatory control rather than erythropoiesis. |
| Inflammatory Modulation | Neuropathy and tissue-injury models | Published work suggests ARA-290 may reduce tissue-damaging inflammatory signaling, which has been discussed as a reason for symptomatic improvement in neuropathy research without conventional analgesic activity. |
| Nerve Fiber Repair and Regrowth Biology | Corneal and skin nerve-fiber studies | Some of the most discussed clinical findings involve changes in corneal nerve fiber density and skin nerve fiber abundance, making ARA-290 of particular interest in structural nerve-fiber recovery research. |
| Tissue Protection Without Erythropoiesis | EPO-derived biology research | ARA-290 was engineered to capture part of erythropoietin's protective signaling profile while reducing the red-blood-cell-stimulating component that limits EPO's broader use in tissue-repair contexts. |
| Anti-Apoptotic Cellular Signaling | Nephrotoxicity and organ-protection models | Preclinical studies suggest ARA-290 may shield cells from damage caused by toxins or chemotherapeutic agents, including cisplatin, through downstream repair cascade activation. |
The innate repair receptor is described in the ARA-290 literature as a heteromeric complex involving the erythropoietin receptor (EPOR) and CD131, a beta common receptor subunit. This receptor system is associated with cytoprotection, tissue repair, and inflammatory control, not classical erythropoiesis. ARA-290 is proposed to selectively engage this complex rather than the homodimeric EPOR responsible for red blood cell production.
ARA-290 has been studied across several experimental and early clinical contexts. The following summarizes the primary research domains represented in the published literature.
| Research Area | Study Context | Nature of Findings |
|---|---|---|
| Small Fiber Neuropathy (SFN) | Sarcoidosis-associated SFN trials | A randomized pilot study reported improvement in SFN symptom scores with an acceptable safety profile. A later dose-ranging study reported significantly increased small nerve fiber abundance in the cornea and skin, described by authors as consistent with a disease-modifying effect in neuropathy research settings. |
| Type 2 Diabetes with Neuropathic Symptoms | Phase 2 human study (2015) | ARA-290 was associated with improvements in neuropathic symptom measures and observed changes in corneal nerve fiber density in a subgroup with reduced baseline nerve fiber abundance. Evidence is early and not definitive. |
| Ocular and Retinal Research | Diabetic macular edema and corneal nerve studies | A phase 2 clinical trial evaluated cibinetide for diabetic macular edema. Corneal nerve-fiber outcomes have been a recurring biomarker across multiple ARA-290 studies, reflecting interest in tissue-protective signaling in metabolically stressed tissues. |
| Inflammatory Modulation and Tissue Repair | Mechanistic and preclinical review literature | Reviews describe ARA-290 as part of a broader effort to reprogram tissue-damaging inflammatory environments toward repair. This is one of the central ideas behind its mechanism-oriented scientific interest. |
| Organ Protection Models | Ischemia-reperfusion and nephrotoxicity studies | Preclinical studies explore ARA-290 in kidney transplantation models by reducing post-reperfusion inflammation, and in nephrotoxicity models involving cisplatin. Findings are mechanistic and experimental. |
| Cardiac and Metabolic Research | Age-related cardiac inflammation and HbA1c models | Newer research (2023 onward) has examined ARA-290 in models involving age-related cardiac inflammation, systolic function preservation, and metabolic control including HbA1c and lipid profiles in type 2 diabetes research settings. |
Understanding ARA-290 requires understanding how and why it differs from erythropoietin, the protein it is derived from. These are not interchangeable compounds.
| Feature | ARA-290 (Cibinetide) | Erythropoietin (EPO) |
|---|---|---|
| Size | 11 amino acids (small synthetic peptide) | 165 amino acids (glycoprotein) |
| Red blood cell production | Non-hematopoietic: does not stimulate RBC production | Stimulates red blood cell production through classical erythropoietic signaling |
| Target receptor | Innate repair receptor (EPOR/CD131 heteromer) | Classical EPO receptor (EPOR homodimer) |
| Primary research focus | Neuropathy, inflammation, tissue repair, corneal nerve biology | Anemia treatment, red blood cell stimulation |
| Known risks in studies | No significant adverse signals in published trials to date | Thrombosis risk, elevated blood viscosity with supraphysiologic dosing |
| Design intent | Engineered to capture tissue-protective EPO biology without hematopoietic effects | Endogenous hormone produced by the kidneys; not engineered for selectivity |
ARA-290 has a distinctive pharmacokinetic profile that differentiates it from many longer research peptides.
| Parameter | Detail | Research Significance |
|---|---|---|
| Plasma half-life | Approximately 2 minutes | Despite the short plasma half-life, biological effects in studies persist considerably longer due to downstream intracellular repair cascade activation. |
| Administration route in studies | Subcutaneous injection | Subcutaneous delivery is the most frequent route in published neuropathy and metabolic studies, typically over 4 to 12 week protocols. |
| Research dosing range | 1 mg to 8 mg per day in published studies | Dose-ranging studies have evaluated this range in sarcoidosis-associated SFN and type 2 diabetes neuropathy contexts. |
| Lyophilized storage | -20°C | Standard lyophilized peptide storage conditions apply. Sequence integrity must be preserved prior to reconstitution. |
| Post-reconstitution storage | 2-8°C | Once reconstituted, keep refrigerated and use within the appropriate research window. Avoid repeated freeze-thaw cycles. |
| Environmental exposure | Avoid heat, light, and moisture | All three accelerate degradation and compromise compound integrity before and after reconstitution. |
ARA-290 has a growing but still limited human evidence base. Researchers and readers should interpret the literature with the following boundaries in mind.
For a compound studied in neuropathy and tissue-repair contexts, the quality of the supplied material is directly relevant to research validity. These are the standards that matter most.
| Standard | Why It Matters for ARA-290 Research |
|---|---|
| Third-party HPLC testing | Independent verification confirms the compound meets research-grade purity standards. For an 11-amino-acid engineered peptide, sequence accuracy and purity are both essential. |
| Mass spectrometry identity confirmation | Confirms molecular weight and sequence identity, not just chromatographic purity. Critical for a peptide with a specific engineered structure derived from EPO. |
| Batch-specific COA availability | Lot-level traceability allows researchers to document exactly which material was used and compare results across batches or protocols. |
| 99%+ purity threshold | Lower purity introduces unknown impurities that add uncontrolled variables into neuropathy and tissue-protection research models. |
| Research-use-only labeling | Keeps the compound correctly framed as a laboratory material and ensures regulatory compliance in both Canada and the USA. |
These pages extend the repair-signaling, neuropeptide, and Canadian research quality context surrounding ARA-290.
These answers cover the most common ARA-290 research and sourcing questions from researchers in Canada and the USA in 2026.
ARA-290, also known as cibinetide, is an 11-amino-acid synthetic peptide engineered from the tissue-protective helix B surface region of erythropoietin. CAS number: 1208243-50-8. PubChem CID: 91810664. It is categorized as a repair-oriented research peptide studied for innate repair receptor signaling, inflammatory modulation, small fiber neuropathy, and tissue-protective biology.
Yes. Cibinetide is the International Nonproprietary Name (INN) associated with ARA-290. The two names refer to the same compound. PHBSP is also listed as a synonym in some databases.
ARA-290 is primarily studied in connection with small fiber neuropathy, inflammatory signaling, tissue repair, corneal nerve-fiber density changes, diabetic neuropathic symptoms, and related protective biology. Newer research has also explored cardiac and metabolic contexts. Published human evidence is still limited and concentrated in specific research populations.
No. ARA-290 is derived from a specific tissue-protective region of erythropoietin, but it is a distinct 11-amino-acid engineered peptide with a different receptor target and biological profile. It does not stimulate red blood cell production the way erythropoietin does and should not be treated as equivalent to EPO in any research context.
The literature describes ARA-290 as a nonerythropoietic peptide designed to avoid the classical erythropoietic effects associated with erythropoietin. Its proposed mechanism involves the innate repair receptor rather than the classical EPOR homodimer that drives red blood cell production.
ARA-290 has a plasma half-life of approximately 2 minutes. Despite this, biological effects in published studies persist considerably longer. Researchers attribute this to downstream intracellular repair cascade activation that continues beyond plasma clearance of the peptide itself.
Yes, but it is still limited. Early studies in sarcoidosis-associated small fiber neuropathy and type 2 diabetes with neuropathic symptoms reported encouraging signals. A phase 2 trial also evaluated ARA-290 for diabetic macular edema. Larger definitive evidence is still needed. Strong clinical conclusions are not justified by the current evidence base.
All Luxara Labs peptides, including ARA-290, are tested to a minimum of 99% purity by independent third-party HPLC and mass spectrometry analysis. A batch-specific Certificate of Analysis (COA) is available for every order. Verification is performed by independent labs before any product is released.
The following peer-reviewed references and database records support the molecular, mechanistic, and clinical content discussed on this page. All links direct to verified primary sources.
Join our list and get an instant 10% discount code — valid for first-time buyers.
